Pharmacopsychiatry 2004; 37(6): 303-304
DOI: 10.1055/s-2004-832689
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Clozapine and Pregnancy

A Case HistoryH. Karakuła1 , K. Szajer1 , B. Śpila1 , A. Grzywa1 , M. Chuchra1
  • 1Dept. of Psychiatry, Medical University of Lublin, Lublin, Poland
Further Information

Publication History

Received: 15.4.2003 Revised: 11.9.2003

Accepted: 21.1.2004

Publication Date:
19 November 2004 (online)

Preview

Introduction

According to the FDA, clozapine [1] is listed in category B [4], which includes drugs for which there is a lack of evidence about its teratogenic effects in humans. In the opinion of some investigators, the use of clozapine during pregnancy is connected with the potential risk of birth defects (category C), for example retinopathy [8] and toxic effects of a newborn: seizures and withdrawal phenomenon [9], gastroesophageal reflux [2], neonatal risk of clozapine-induced agranulocytosis [7] and risk of ”floppy infant syndrome” [3]. Based on the report of the Novartis it can be confirmed that clozapine is not a major teratogen [4].

References

H. Karakula, M.D., PhD.

Department of Psychiatry

Medical University of Lublin

Ul. Kurantowa 4 m. 117

20-836 Lublin

Poland

Email: karakulahw@poczta.onet.pl